FDA rejects 3+ high-profile drug applications in Q4 2026

Under interim leadership or short-term guidance, the FDA will exhibit unpredictability by rejecting multiple promising drug applications, similar to Makary’s tenure. This reflects ongoing internal instability and the absence of a cohesive regulatory strategy.

Implied probability (Yes)

60%